JP2015519382A - 治療用抗体のための医薬処方物 - Google Patents

治療用抗体のための医薬処方物 Download PDF

Info

Publication number
JP2015519382A
JP2015519382A JP2015516595A JP2015516595A JP2015519382A JP 2015519382 A JP2015519382 A JP 2015519382A JP 2015516595 A JP2015516595 A JP 2015516595A JP 2015516595 A JP2015516595 A JP 2015516595A JP 2015519382 A JP2015519382 A JP 2015519382A
Authority
JP
Japan
Prior art keywords
antibody
concentration
pharmaceutical composition
formulation
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015516595A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519382A5 (OSRAM
Inventor
フランク ミカエル
フランク ミカエル
シュテファン バサラブ
シュテファン バサラブ
アンナ マリア アイボフナー
アンナ マリア アイボフナー
シルケ ミューラウ
シルケ ミューラウ
マルクス ウォルフラム
マルクス ウォルフラム
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2015519382A publication Critical patent/JP2015519382A/ja
Publication of JP2015519382A5 publication Critical patent/JP2015519382A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015516595A 2012-06-12 2013-06-12 治療用抗体のための医薬処方物 Pending JP2015519382A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12171617.9 2012-06-12
EP12171617 2012-06-12
PCT/EP2013/062063 WO2013186230A1 (en) 2012-06-12 2013-06-12 Pharmaceutical formulation for a therapeutic antibody

Publications (2)

Publication Number Publication Date
JP2015519382A true JP2015519382A (ja) 2015-07-09
JP2015519382A5 JP2015519382A5 (OSRAM) 2016-03-24

Family

ID=48579114

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015516595A Pending JP2015519382A (ja) 2012-06-12 2013-06-12 治療用抗体のための医薬処方物

Country Status (4)

Country Link
US (1) US20150150982A1 (OSRAM)
EP (1) EP2863951A1 (OSRAM)
JP (1) JP2015519382A (OSRAM)
WO (1) WO2013186230A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019525902A (ja) * 2016-06-30 2019-09-12 セルトリオン・インコーポレイテッド 安定な液体医薬製剤
JP2021120393A (ja) * 2016-10-21 2021-08-19 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
KR101730694B1 (ko) * 2012-03-07 2017-04-27 카딜라 핼쓰캐어 리미티드 TNF-α 항체의 약제학적 제형
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
JP2015520625A (ja) * 2012-04-23 2015-07-23 ゾゲニクス インコーポレーティッド 薬物送達カプセルのためのピストン施栓
WO2013165791A1 (en) * 2012-05-03 2013-11-07 Boehringer Ingelheim International Gmbh Anti-il-23p19 antibodies
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
PE20191815A1 (es) 2012-09-07 2019-12-27 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
CN106170298B (zh) 2013-10-16 2024-01-09 前瞻疗法公司 用于提高抗体稳定性的缓冲液制剂
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3050557A1 (en) 2014-05-23 2016-08-03 Ares Trading S.A. Liquid pharmaceutical composition
EP2946766B1 (en) * 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
KR20170018810A (ko) 2014-06-10 2017-02-20 메이지 세이카 파루마 가부시키가이샤 안정한 아달리무맙 수성 제제
EP3209332B1 (en) 2014-10-23 2021-05-26 Amgen Inc. Reducing viscosity of pharmaceutical formulations
HUP1400510A1 (hu) 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
AR103544A1 (es) * 2015-01-28 2017-05-17 Mabxience S A FORMULACIONES FARMACÉUTICAS PARA ANTICUERPOS ANTI-TNF-a
IL307578A (en) 2015-02-04 2023-12-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
EP3693469A1 (en) * 2015-04-27 2020-08-12 Momenta Pharmaceuticals, Inc. Method of manufacturing a therapeutic protein
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
MX2018009341A (es) 2016-02-03 2019-05-15 Oncobiologics Inc Formulaciones tamponadas para una mayor estabilidad de anticuerpos.
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
CN108686204A (zh) * 2017-04-07 2018-10-23 浙江海正药业股份有限公司 包含组氨酸缓冲体系的英夫利西单抗组合物
KR20210021299A (ko) 2018-05-10 2021-02-25 리제너론 파아마슈티컬스, 인크. 고농도 vegf 수용체 융합 단백질 함유 제제
WO2020138517A1 (ko) * 2018-12-24 2020-07-02 삼성바이오에피스 주식회사 항-TNFα 항체를 포함하는 약제학적 조성물
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
CN113546252A (zh) * 2020-04-24 2021-10-26 上海君实生物医药科技股份有限公司 抗pcsk9抗体的药物递送装置

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2006511457A (ja) * 2002-08-16 2006-04-06 アボツト・バイオテクノロジー・リミテツド Ｔｎｆ−アルファ関連疾患の治療用ヒト抗体の製剤
WO2010129469A1 (en) * 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
JP2011518110A (ja) * 2007-11-30 2011-06-23 アボット・ラボラトリーズ タンパク質製剤及びその製造方法
WO2011104381A2 (en) * 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
JP2012502976A (ja) * 2008-09-19 2012-02-02 ファイザー・インク 安定な液体抗体配合物
WO2012037430A1 (en) * 2010-09-17 2012-03-22 Abbott Laboratories Raman spectroscopy for bioprocess operations
JP2012510468A (ja) * 2008-11-28 2012-05-10 アボット・ラボラトリーズ 安定な抗体組成物およびこれを安定させるための方法
WO2012065072A2 (en) * 2010-11-11 2012-05-18 Abbott Biotechnology Ltd. IMPROVED HIGH CONCENTRATION ANTI-TNFα ANTIBODY LIQUID FORMULATIONS
WO2012089778A1 (en) * 2010-12-28 2012-07-05 Hexal Ag Pharmaceutical formulation comprising a biopharmaceutical drug
WO2012121754A1 (en) * 2011-03-09 2012-09-13 Janssen Biotech Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
WO2013011076A2 (en) * 2011-07-19 2013-01-24 Glaxo Group Limited Antigen-binding proteins with increased fcrn binding
CN102988984A (zh) * 2012-12-21 2013-03-27 嘉和生物药业有限公司 增强稳定性的抗TNF-α人单克隆抗体的含水药物制剂
WO2013164837A1 (en) * 2012-03-07 2013-11-07 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies
WO2014099636A1 (en) * 2012-12-18 2014-06-26 Merck Sharp & Dohme Corp. Liquid formulations for an anti-tnf alpha antibody

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2006511457A (ja) * 2002-08-16 2006-04-06 アボツト・バイオテクノロジー・リミテツド Ｔｎｆ−アルファ関連疾患の治療用ヒト抗体の製剤
JP2011518110A (ja) * 2007-11-30 2011-06-23 アボット・ラボラトリーズ タンパク質製剤及びその製造方法
JP2012502976A (ja) * 2008-09-19 2012-02-02 ファイザー・インク 安定な液体抗体配合物
JP2012510468A (ja) * 2008-11-28 2012-05-10 アボット・ラボラトリーズ 安定な抗体組成物およびこれを安定させるための方法
WO2010129469A1 (en) * 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
WO2011104381A2 (en) * 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
WO2012037430A1 (en) * 2010-09-17 2012-03-22 Abbott Laboratories Raman spectroscopy for bioprocess operations
WO2012065072A2 (en) * 2010-11-11 2012-05-18 Abbott Biotechnology Ltd. IMPROVED HIGH CONCENTRATION ANTI-TNFα ANTIBODY LIQUID FORMULATIONS
WO2012089778A1 (en) * 2010-12-28 2012-07-05 Hexal Ag Pharmaceutical formulation comprising a biopharmaceutical drug
WO2012121754A1 (en) * 2011-03-09 2012-09-13 Janssen Biotech Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
WO2013011076A2 (en) * 2011-07-19 2013-01-24 Glaxo Group Limited Antigen-binding proteins with increased fcrn binding
WO2013164837A1 (en) * 2012-03-07 2013-11-07 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies
WO2014099636A1 (en) * 2012-12-18 2014-06-26 Merck Sharp & Dohme Corp. Liquid formulations for an anti-tnf alpha antibody
CN102988984A (zh) * 2012-12-21 2013-03-27 嘉和生物药业有限公司 增强稳定性的抗TNF-α人单克隆抗体的含水药物制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 78, JPN6016044586, 13 March 2011 (2011-03-13), pages 208 - 212, ISSN: 0003442865 *
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 185, JPN6016044585, 1999, pages 129 - 188, ISSN: 0003442864 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019525902A (ja) * 2016-06-30 2019-09-12 セルトリオン・インコーポレイテッド 安定な液体医薬製剤
JP7082070B2 (ja) 2016-06-30 2022-06-07 セルトリオン・インコーポレイテッド 安定な液体医薬製剤
JP2022122941A (ja) * 2016-06-30 2022-08-23 セルトリオン・インコーポレイテッド 安定な液体医薬製剤
JP7405324B2 (ja) 2016-06-30 2023-12-26 セルトリオン・インコーポレイテッド 安定な液体医薬製剤
US11951207B2 (en) 2016-06-30 2024-04-09 Celltrion Inc. Stable liquid pharmaceutical preparation
JP2021120393A (ja) * 2016-10-21 2021-08-19 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
JP2024010026A (ja) * 2016-10-21 2024-01-23 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
US12214013B2 (en) 2016-10-21 2025-02-04 Amgen Inc. Methods of treatment of arthritis and/or psoriasis with pharmaceutical formulations of etanercept
JP7754903B2 (ja) 2016-10-21 2025-10-15 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法

Also Published As

Publication number Publication date
US20150150982A1 (en) 2015-06-04
WO2013186230A1 (en) 2013-12-19
EP2863951A1 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
JP2015519382A (ja) 治療用抗体のための医薬処方物
JP6438599B2 (ja) 抗ｃｇｒｐ抗体製剤
JP5631591B2 (ja) 安定な抗体製剤
KR102667484B1 (ko) 안정한 항체 제형
JP4361280B2 (ja) 安定な抗体液体製剤
AU2018306612B2 (en) High concentration anti-C5 antibody formulations
JP6271682B2 (ja) 抗ｐｃｓｋ９抗体を含む安定化製剤
EP2714009B1 (en) Stable liquid formulation of etanercept
JP5577098B2 (ja) ポリペプチドを含有する安定な緩衝化された製剤
CN104023748A (zh) 含有氨基酸的蛋白质制剂
CA2866692A1 (en) Formulations which prevent formation of antibody aggregates
US20210070852A1 (en) Anti-IL-23p19 Antibody Formulations
WO2015121318A1 (en) Anti-il-4/anti-il-13 bispecific antibody/polyglutamate formulations
EP3071181A1 (en) Pharmaceutical composition of an anti-vegf antibody
JP2020534255A (ja) 治療用タンパク質の凍結乾燥医薬配合物のためのプロセス
JP2023166014A (ja) コラーゲン７組成物及びそれを用いる方法
JP7674369B2 (ja) 安定な抗体製剤
Allmendinger Opportunities in an evolving pharmaceutical development landscape: Product differentiation of biopharmaceutical drug products
CN114129723A (zh) 一种高浓度抗her2的抗体制剂及其用途
AU2019314355A1 (en) Pharmaceutical formulations of masked antibodies
US20230085357A1 (en) Injectable high concentration pharmaceutical formulations and methods of manufacturing and use thereof
Nithya Review on monoclonal antibodies –Manufacturing aspects, tactics, and future prospects
JP2024540351A (ja) Ｃ５結合タンパク質の投与
Masand Design of therapeutic antibody formulations for subcutaneous delivery
KR20230165828A (ko) 항-MUC16 x 항-CD3 이중특이적 항체를 함유하는 안정화된 제형

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170712